Overview

Central Nervous System(CNS) Efficacy of Dacomitinib

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center